Haemonetics Co. (NYSE:HAE) Short Interest Update


Share on StockTwits

Haemonetics Co. (NYSE:HAE) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,950,000 shares, a growth of 23.4% from the March 31st total of 1,580,000 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average daily trading volume, of 647,500 shares, the short-interest ratio is presently 3.0 days.

Shares of Haemonetics stock opened at $65.61 on Tuesday. The company has a current ratio of 2.25, a quick ratio of 1.34 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $102.18 and its two-hundred day simple moving average is $114.01. The company has a market cap of $3.33 billion, a P/E ratio of 31.70, a PEG ratio of 5.17 and a beta of 0.56. Haemonetics has a 12-month low of $65.45 and a 12-month high of $142.11.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Monday, February 1st. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.16. The business had revenue of $240.00 million for the quarter, compared to the consensus estimate of $224.29 million. Haemonetics had a net margin of 11.76% and a return on equity of 22.85%. The company’s quarterly revenue was down 7.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. Analysts predict that Haemonetics will post 2.45 EPS for the current fiscal year.

In related news, VP Dan Goldstein sold 2,671 shares of the business’s stock in a transaction that occurred on Thursday, February 4th. The shares were sold at an average price of $135.86, for a total transaction of $362,882.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard J. Meelia sold 10,353 shares of the business’s stock in a transaction that occurred on Thursday, February 4th. The shares were sold at an average price of $134.64, for a total transaction of $1,393,927.92. The disclosure for this sale can be found here. Insiders have sold 13,194 shares of company stock valued at $1,777,115 in the last 90 days. 1.63% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in HAE. Meeder Asset Management Inc. boosted its stake in Haemonetics by 7,350.0% in the 1st quarter. Meeder Asset Management Inc. now owns 298 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 294 shares in the last quarter. Berman Capital Advisors LLC bought a new position in Haemonetics in the 4th quarter worth about $47,000. IFP Advisors Inc lifted its stake in Haemonetics by 531.0% during the 4th quarter. IFP Advisors Inc now owns 530 shares of the medical instruments supplier’s stock valued at $62,000 after acquiring an additional 446 shares during the period. IronBridge Private Wealth LLC bought a new position in Haemonetics during the 4th quarter valued at about $119,000. Finally, Dupont Capital Management Corp lifted its stake in Haemonetics by 330.2% during the 4th quarter. Dupont Capital Management Corp now owns 1,424 shares of the medical instruments supplier’s stock valued at $169,000 after acquiring an additional 1,093 shares during the period. Institutional investors own 96.22% of the company’s stock.

Several equities research analysts have issued reports on HAE shares. Morgan Stanley reiterated an “equal weight” rating and set a $83.00 target price (down from $147.00) on shares of Haemonetics in a research report on Monday, April 26th. CJS Securities lowered shares of Haemonetics from an “outperform” rating to a “market perform” rating in a report on Monday, April 19th. Raymond James boosted their price objective on shares of Haemonetics from $145.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. JMP Securities boosted their price objective on shares of Haemonetics from $110.00 to $140.00 in a report on Thursday, January 21st. Finally, Barrington Research lowered their price objective on shares of Haemonetics from $140.00 to $91.00 and set an “outperform” rating for the company in a report on Monday, April 26th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $117.00.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.